Point-of-Care Testing (POCT) Market – Trends and Forecast To 2024
©
Global Point-of-care Testing (POCT) Market By Product (Blood Glucose Testing Kits, Cardiometabolic Monitoring Kits, Infectious Disease Testing Kits, Cholesterol Testing Kits, Pregnancy & Fertility Tests Kits, Tumor/Cancer Markers, Urinalysis Testing Kits, Cholesterol Test Strips, Hematology Testing Kits, Drugs Of Abuse Testing Kits, Fecal Occult Testing Kits, Rapid Coagulation Testing Kits, & Others),By Prescription Mode (Prescription Based Testing & Over-The-Counter Testing),By Distribution Channel (Direct Tenders & Retail),By End User (Hospital, Clinics, Ambulatory Care, Home Healthcare, & Research Laboratory), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Trends and Forecast to 2024
The Global point-of-care testing market is expected to reach USD 35.3 billion by 2024 from USD 18.6 billion in 2016, growing at a CAGR of 8.4% in the forecast period 2017 to 2024
Request for Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=point-care-testing-poct-market
Segmentation:
By Product (Blood Glucose Testing Kits, Cardiometabolic Monitoring Kits, Infectious Disease Testing Kits, Cholesterol Testing Kits, Pregnancy & Fertility Tests Kits, Tumor/Cancer Markers, Urinalysis Testing Kits, Cholesterol Test Strips, Hematology Testing Kits, Drugs Of Abuse Testing Kits, Fecal Occult Testing Kits, Rapid Coagulation Testing Kits, & Others), Prescription Mode (Prescription Based Testing & Over-The-Counter Testing), Distribution Channel (Direct Tenders & Retail), End User (Hospital, Clinics, Ambulatory Care, Home Healthcare, & Research Laboratory), Geography (North America, Europe, Asia-Pacific, South America, Rest of the World).
Drivers:
Some of the major factors driving the market for Point-Of-Care Testing Market, such as increasing geriatric population, increase in infectious diseases (hepatitis, HIV infection, influenza, respiratory infections and others), technological advancements, introduction of home-based point of care devices, and rapid economic development in the emerging economies. These factors such as increased awareness among the population, ease of use, rapid test, right dosage to the right place, and enhanced patient compliance are also driving the growth for the point-of-care testing market.
GROWING GERIATRIC POPULATION
Improved economic growth, better healthcare, and growthin access to education have led to longer life expectancy in most socio-economic groups. Due to growing geriatric population, the cases of acute and chronic diseases are rising. Older population is more prone to diseases such as diabetes, infections, cardiometabolic risks and cancer. The normal aging process causes a variety of physical and emotional issues that can be difficult for both the geriatric patient and healthcare worker to understand their needs and be sensitive in their treatment
ADVANCEMENT IN TECHNOLOGY
POCT technologies are evolving, and this market segment is growing at a rapid pace. The use of POCT has evolved further since 2013, with high range of professional and self-monitoring tests into the ambulatory setting with a patient centric focus.. The need to improve patient safety and outcomes through rapid testing with trustworthy and actionable results at the point of care has provided significant benefits, including the ability to provide immediate and appropriate medical intervention. A continuous effort and progress has been made by manufacturers to create products with newer, advanced technologies with reduced sample volume or less blood on portable devices
DECENTRALIZED LABORATORY TESTING
For decentralized lab testing, there are two drivers i.e., need for better drug monitoring for diseases like cancer and increasing virulence of infectious diseases. Molecular testing for hospital acquired infections has risen over the last several years so as to reduce cost and length of stay (LOS). Most of the molecular diagnostic tests are carried out in large reference lab or in CLIA-accredited labs but due to more availability of molecular diagnostic tests (specifically for conditions giving a quick result) decentralized labs ora push towards decentralized testing and near-patient settings are seen as a feasible and growing market
INCREASED INCIDENCE OF CHRONIC DISEASES
Cardiovascular diseases (CVD), various respiratory and infectious diseases continue to be the main cause of mortality representing about 30% of all deaths worldwide. Chronic diseases like hypertension, diabetes mellitus, and obesity are at the major risk factors for the occurrence of CVD. With the fast economic development and increasing westernization of lifestyle in the last few decades has lead to the increase in the prevalence rate of these diseases enormously driving the demand for point-of-care diagnostic market in the coming years
LABORATORY STAFF SHORTAGES
Laboratory staff shortages or lack of skilled tec hnicians is another factor driving the development of POC test especially in the field of medical diagnostics, unavailability of skilled staff is increasing and due to this reason there is an increase in the level of automation and self-contained systems that involves negligible user interaction. Therefore, this shortage of skilled staff will accelerate the market penetration rates of POC diagnostic products. Another factor for growth in the point of care market will be driven by elderly patient’s preference for home monitoring and government initiatives aimed at increasing the adoption of point-of-care testing to cut costs.
The global point-of-care testing market is segmented on the basis of product into prescription mode, distribution channel, end user, and geography.
Browse Full Report with Details TOC @ http://databridgemarketresearch.com/reports/point-care-testing-poct-market/
Based on geography, the market is segmented into five geographical regions:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa
The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.
Some major factors driving the market for Point-Of-Care Testing market, such as increasing geriatric population, increase in infectious diseases (hepatitis, HIV infection, influenza, respiratory infections and others), technological advancements, introduction of home-based point of care devices, and rapid economic development in the emerging economies. These factors such as increased awareness among the population, ease of use, rapid test, right dosage to the right place, and enhanced patient compliance are also driving the growth for the point-of-care testing market.
Some of the major players operating in this market are
• Siemens AG
• Abbott Laboratories, Inc.
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• Johnson & Johnson
• Alere Inc.
• Instrumentation Laboratory
• PTS Diagnostics
• Abaxis, Inc.
• Medtronic
• Accriva Diagnostics
• OPTI Medical
• Sienco, Inc.
• Alpha Scientific
• AccuBioTech Co., Ltd.
• ACON Laboratories, Inc.
• Acrongenomics, Inc.
• bioMérieux SA
• Biomerica, Inc
• Atlas Genetics Ltd.
• Alfa Scientific Designs, Inc.
• Bio-Rad Laboratories, Inc.
• Medica Corporation
• Nova Biomedica
Inquiry before Buying @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=point-care-testing-poct-market
Table Of Content:
1. INTRODUCTION
1.1. OVERVIEW OF THE GLOBAL POINT-OF-CARE TESTING MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL POINT-OF-CARE TESTING MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. PRODUCT PIPELINE ANALYSIS
2.2.6. PORTER’S FIVE FORCES MATRIX
2.3. GLOBAL POINT-OF-CARE TESTING MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL POINT-OF-CARE TESTING MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. HIGH PREVALENCE OF INFECTIOUS DISEASES IN DEVELOPING COUNTRIES
4.3.1.2. INCREASING INCIDENCE OF LIFESTYLE DISEASES
4.3.1.3. RISING USAGE OF HOME-BASED POC DEVICES
4.3.1.4. GROWING NUMBER OF REGULATORY APPROVALS FOR NOVEL IMMUNOASSAY TECHNIQUES
4.3.1.5. SHORTAGE OF SKILLED LABORATORY TECHNICIANS INCREASING PREFERENCE OF POC TESTING
4.3.1.6. RISING INCIDENCE OF UNPLANNED PREGANANCIES
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.4. THREATS
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. POINT-OF-CARE TESTING MARKET, BY TYPE
5.1. OVERVIEW
5.2. CARDIOMETABOLIC MONITORING KITS, BY PRODUCT TYPE
5.2.1. CARDIAC MARKERS
5.2.2. BLOOD GAS ELECTROLYTE TESTING KITS
5.2.3. HBA1C TESTING KITS
5.2.4. LIPID TESTING KITS
5.3. INFECTIOUS DISEASE TESTING KITS, BY PRODUCT TYPE
5.3.1. INFLUENZA TESTING KITS
5.3.2. HIV TESTING KITS
5.3.3. HEPATITIS C TESTING KITS
5.3.4. STD TESTING KITS
5.3.5. TROPICAL DISEASE TESTING KITS
5.3.6. HEALTHCARE ASSOCIATED INFECTIONS TESTING KITS
5.3.7. RESPIRATORY INFECTIONS TESTING KITS
5.3.8. OTHERS
5.4. CHOLESTROL TESTING KITS, BY PRODUCT TYPE
5.4.1. PROTHROMBIN TIME TESTING KITS
5.4.2. ACTIVATED CLOTTING TIME TESTING KITS
5.5. BLOOD GLUCOSE TESTING KITS
5.6. PREGNANCY AND FERTILITY TESTING KITS
5.7. TUMOR CANCER MARKERS
5.8. URINALYSIS TESTING KITS
5.9. HEMATOLOGY TESTING KITS
5.10. DRUGS OF ABUSE TESTING KITS
5.11. FECAL OCCULT TESTING KITS
5.12. RAPID COAGULATION TESTING KITS
5.13. OTHERS
6. POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE
6.1. OVERVIEW
6.2. PRESCRIPTION BASED TESTING KITS
6.3. OVER THE COUNTER (OTC) BASED TESTING KITS
7. POINT-OF-CARE TESTING MARKET, BY END-USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. CLINICS
7.4. AMBULATORY CARE
7.5. HOME HEALTHCARE
7.6. RESEARCH LABORATORY
8. POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DIRECT TENDERS
8.3. RETAIL
9. POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE POINT OF CARE TESTING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.1.2. EUROPE
9.1.2.1. GERMANY
9.1.2.2. FRANCE
9.1.2.3. U.K.
9.1.2.4. ITALY
9.1.2.5. SPAIN
9.1.2.6. RUSSIA
9.1.2.7. TURKEY
9.1.2.8. BELGIUM
9.1.2.9. NETHERLANDS
9.1.2.10. SWITZERLAND
9.1.2.11. REST OF EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.3.1. JAPAN
9.1.3.2. CHINA
9.1.3.3. SOUTH KOREA
9.1.3.4. INDIA
9.1.3.5. AUSTRALIA
9.1.3.6. SINGAPORE
9.1.3.7. THAILAND
9.1.3.8. MALAYSIA
9.1.3.9. INDONESIA
9.1.3.10. PHILIPPINES
9.1.3.11. REST OF APAC
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10. POINT-OF-CARE TESTING MARKET: COMPETITIVE LANDSCAPE
10.1. GLOBAL POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.2. U.S. POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.4. APAC POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.5. SOUTH AMERICA POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.6. MEA POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.7. MERGERS & ACQUISITIONS
10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
10.9. EXPANSIONS
10.10. REGULATORY CHANGES
10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11. POINT-OF-CARE TESTING MARKET: COMPANY PROFILES
11.1. ABBOTT LABORATORIES, INC.
11.1.1 COMPANY OVERVIEW
11.1.2 SWOT ANALYSIS
11.1.3 REVENUE ANALYSIS
11.1.4 PRODUCT PORTFOLIO
11.1.5 RECENT DEVELOPEMENTS
11.1.6 DATA BRIDGE ANALYSIS
11.2. ROCHE DIAGNOSTICS LIMITED
11.2.1 COMPANY OVERVIEW
11.2.2 SWOT ANALYSIS
11.2.3 REVENUE ANALYSIS
11.2.4 PRODUCT PORTFOLIO
11.2.5 RECENT DEVELOPEMENTS
11.2.6 DATA BRIDGE ANALYSIS
11.3. SIEMENS AG
11.3.1 COMPANY OVERVIEW
11.3.2 SWOT ANALYSIS
11.3.3 REVENUE ANALYSIS
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPEMENTS
11.3.6 DATA BRIDGE ANALYSIS
11.4. BECKMAN COULTER, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 SWOT ANALYSIS
11.4.3 REVENUE ANALYSIS
11.4.4 PRODUCT PORTFOLIO
11.4.5 RECENT DEVELOPEMENTS
11.4.6 DATA BRIDGE ANALYSIS
11.5. BECTON, DICKINSON AND COMPANY
11.5.1 COMPANY OVERVIEW
11.5.2 SWOT ANALYSIS
11.5.3 REVENUE ANALYSIS
11.5.4 PRODUCT PORTFOLIO
11.5.5 RECENT DEVELOPEMENTS
11.5.6 DATA BRIDGE ANALYSIS
11.6. JOHNSON & JOHNSON
11.6.1 COMPANY OVERVIEW
11.6.2 SWOT ANALYSIS
11.6.3 REVENUE ANALYSIS
11.6.4 PRODUCT PORTFOLIO
11.6.5 RECENT DEVELOPEMENTS
11.6.6 DATA BRIDGE ANALYSIS
11.7. ALERE INC.
11.7.1 COMPANY OVERVIEW
11.7.2 SWOT ANALYSIS
11.7.3 REVENUE ANALYSIS
11.7.4 PRODUCT PORTFOLIO
11.7.5 RECENT DEVELOPEMENTS
11.7.6 DATA BRIDGE ANALYSIS
11.8. INSTRUMENTATION LABORATORY
11.8.1 COMPANY OVERVIEW
11.8.2 SWOT ANALYSIS
11.8.3 REVENUE ANALYSIS
11.8.4 PRODUCT PORTFOLIO
11.8.5 RECENT DEVELOPEMENTS
11.8.6 DATA BRIDGE ANALYSIS
11.9. PTS DIAGNOSTICS
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.6 DATA BRIDGE ANALYSIS
11.10. ABAXIS, INC.
11.10.1 COMPANY OVERVIEW
11.10.2 SWOT ANALYSIS
11.10.3 REVENUE ANALYSIS
11.10.4 PRODUCT PORTFOLIO
11.10.5 RECENT DEVELOPEMENTS
11.10.6 DATA BRIDGE ANALYSIS
11.11. MEDTRONIC
11.11.1 COMPANY OVERVIEW
11.11.2 SWOT ANALYSIS
11.11.3 REVENUE ANALYSIS
11.11.4 PRODUCT PORTFOLIO
11.11.5 RECENT DEVELOPEMENTS
11.11.6 DATA BRIDGE ANALYSIS
11.12. ACCRIVA DIAGNOSTICS
11.12.1 COMPANY OVERVIEW
11.12.2 SWOT ANALYSIS
11.12.3 REVENUE ANALYSIS
11.12.4 PRODUCT PORTFOLIO
11.12.5 RECENT DEVELOPEMENTS
11.12.6 DATA BRIDGE ANALYSIS
11.13. OPTI MEDICAL
11.13.1 COMPANY OVERVIEW
11.13.2 SWOT ANALYSIS
11.13.3 REVENUE ANALYSIS
11.13.4 PRODUCT PORTFOLIO
11.13.5 RECENT DEVELOPEMENTS
11.13.5 DATA BRIDGE ANALYSIS
11.14. SIENCO, INC.
11.14.1 COMPANY OVERVIEW
11.14.2 SWOT ANALYSIS
11.14.3 REVENUE ANALYSIS
11.14.4 PRODUCT PORTFOLIO
11.14.5 RECENT DEVELOPEMENTS
11.14.6 DATA BRIDGE ANALYSIS
11.15. ALPHA SCIENTIFIC
11.15.1 COMPANY OVERVIEW
11.15.2 SWOT ANALYSIS
11.15.3 REVENUE ANALYSIS
11.15.4 PRODUCT PORTFOLIO
11.15.5 RECENT DEVELOPEMENTS
11.15.6 DATA BRIDGE ANALYSIS
11.16. ACCUBIOTECH CO. LTD.
11.16.1 COMPANY OVERVIEW
11.16.2 SWOT ANALYSIS
11.16.3 REVENUE ANALYSIS
11.16.4 PRODUCT PORTFOLIO
11.16.5 RECENT DEVELOPEMENTS
11.16.5 DATA BRIDGE ANALYSIS
11.17. ACON LABORATORIES, INC.
11.17.1 COMPANY OVERVIEW
11.17.2 SWOT ANALYSIS
11.17.3 REVENUE ANALYSIS
11.17.4 PRODUCT PORTFOLIO
11.17.5 RECENT DEVELOPEMENTS
11.17.6 DATA BRIDGE ANALYSIS
11.18. ACRONGENOMICS
11.18.1 COMPANY OVERVIEW
11.18.2 SWOT ANALYSIS
11.18.3 REVENUE ANALYSIS
11.18.4 PRODUCT PORTFOLIO
11.18.5 RECENT DEVELOPEMENTS
11.18.6 DATA BRIDGE ANALYSIS
11.19. BIOMÉRIEUX, BIOMERICA, INC.
11.19.1 COMPANY OVERVIEW
11.19.2 SWOT ANALYSIS
11.19.3 REVENUE ANALYSIS
11.19.4 PRODUCT PORTFOLIO
11.19.5 RECENT DEVELOPEMENTS
11.19.6 DATA BRIDGE ANALYSIS
11.20. ATLAS GENETICS LTD.
11.20.1 COMPANY OVERVIEW
11.20.2 SWOT ANALYSIS
11.20.3 REVENUE ANALYSIS
11.20.4 PRODUCT PORTFOLIO
11.20.5 RECENT DEVELOPEMENTS
11.20.6 DATA BRIDGE ANALYSIS
11.21. ALFA SCIENTIFIC DESIGNS, INC.
11.21.1 COMPANY OVERVIEW
11.21.2 SWOT ANALYSIS
11.21.3 REVENUE ANALYSIS
11.21.4 PRODUCT PORTFOLIO
11.21.5 RECENT DEVELOPEMENTS
11.21.6 DATA BRIDGE ANALYSIS
11.22. BIO-RAD LABORATORIES, INC.
11.22.1 COMPANY OVERVIEW
11.22.2 SWOT ANALYSIS
11.22.3 REVENUE ANALYSIS
11.22.4 PRODUCT PORTFOLIO
11.22.5 RECENT DEVELOPEMENTS
11.22.6 DATA BRIDGE ANALYSIS
11.23. MEDICA CORPORATION
11.23.1 COMPANY OVERVIEW
11.23.2 SWOT ANALYSIS
11.23.3 REVENUE ANALYSIS
11.23.4 PRODUCT PORTFOLIO
11.23.5 RECENT DEVELOPEMENTS
11.23.6 DATA BRIDGE ANALYSIS
11.24. NOVA BIOMEDICAL
11.24.1 COMPANY OVERVIEW
11.24.2 SWOT ANALYSIS
11.24.3 REVENUE ANALYSIS
11.24.4 PRODUCT PORTFOLIO
11.24.5 RECENT DEVELOPEMENTS
11.24.6 DATA BRIDGE ANALYSIS
12. APPENDIX
12.1. SOURCES AND BIBLIOGRAPHY
12.2. RELATED REPORTS
12.3. A GLIMSE OF DATA BRIDGE MARKET RESEARCH FACTBOOK
13. ABOUT DATA BRIDGE MARKET RESEARCH
Related Report
Global Hemostats Market- Trends and Forecast to 2024
Global Hemostats Market, By Product Type (Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based Hemostat), By Indication (Wound Closure, Surgery), By End-User (Hospitals, Clinics, Ambulatory Centers, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Trends and Forecast to 2024
http://databridgemarketresearch.com/reports/medical-devices/general-surgery-medical-devices/global-hemostats-market-trends-forecast-2024/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Ankit Singh
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog http://databridgemarketresearch.com/blog/
The Global point-of-care testing market is expected to reach USD 35.3 billion by 2024 from USD 18.6 billion in 2016, growing at a CAGR of 8.4% in the forecast period 2017 to 2024
Request for Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=point-care-testing-poct-market
Segmentation:
By Product (Blood Glucose Testing Kits, Cardiometabolic Monitoring Kits, Infectious Disease Testing Kits, Cholesterol Testing Kits, Pregnancy & Fertility Tests Kits, Tumor/Cancer Markers, Urinalysis Testing Kits, Cholesterol Test Strips, Hematology Testing Kits, Drugs Of Abuse Testing Kits, Fecal Occult Testing Kits, Rapid Coagulation Testing Kits, & Others), Prescription Mode (Prescription Based Testing & Over-The-Counter Testing), Distribution Channel (Direct Tenders & Retail), End User (Hospital, Clinics, Ambulatory Care, Home Healthcare, & Research Laboratory), Geography (North America, Europe, Asia-Pacific, South America, Rest of the World).
Drivers:
Some of the major factors driving the market for Point-Of-Care Testing Market, such as increasing geriatric population, increase in infectious diseases (hepatitis, HIV infection, influenza, respiratory infections and others), technological advancements, introduction of home-based point of care devices, and rapid economic development in the emerging economies. These factors such as increased awareness among the population, ease of use, rapid test, right dosage to the right place, and enhanced patient compliance are also driving the growth for the point-of-care testing market.
GROWING GERIATRIC POPULATION
Improved economic growth, better healthcare, and growthin access to education have led to longer life expectancy in most socio-economic groups. Due to growing geriatric population, the cases of acute and chronic diseases are rising. Older population is more prone to diseases such as diabetes, infections, cardiometabolic risks and cancer. The normal aging process causes a variety of physical and emotional issues that can be difficult for both the geriatric patient and healthcare worker to understand their needs and be sensitive in their treatment
ADVANCEMENT IN TECHNOLOGY
POCT technologies are evolving, and this market segment is growing at a rapid pace. The use of POCT has evolved further since 2013, with high range of professional and self-monitoring tests into the ambulatory setting with a patient centric focus.. The need to improve patient safety and outcomes through rapid testing with trustworthy and actionable results at the point of care has provided significant benefits, including the ability to provide immediate and appropriate medical intervention. A continuous effort and progress has been made by manufacturers to create products with newer, advanced technologies with reduced sample volume or less blood on portable devices
DECENTRALIZED LABORATORY TESTING
For decentralized lab testing, there are two drivers i.e., need for better drug monitoring for diseases like cancer and increasing virulence of infectious diseases. Molecular testing for hospital acquired infections has risen over the last several years so as to reduce cost and length of stay (LOS). Most of the molecular diagnostic tests are carried out in large reference lab or in CLIA-accredited labs but due to more availability of molecular diagnostic tests (specifically for conditions giving a quick result) decentralized labs ora push towards decentralized testing and near-patient settings are seen as a feasible and growing market
INCREASED INCIDENCE OF CHRONIC DISEASES
Cardiovascular diseases (CVD), various respiratory and infectious diseases continue to be the main cause of mortality representing about 30% of all deaths worldwide. Chronic diseases like hypertension, diabetes mellitus, and obesity are at the major risk factors for the occurrence of CVD. With the fast economic development and increasing westernization of lifestyle in the last few decades has lead to the increase in the prevalence rate of these diseases enormously driving the demand for point-of-care diagnostic market in the coming years
LABORATORY STAFF SHORTAGES
Laboratory staff shortages or lack of skilled tec hnicians is another factor driving the development of POC test especially in the field of medical diagnostics, unavailability of skilled staff is increasing and due to this reason there is an increase in the level of automation and self-contained systems that involves negligible user interaction. Therefore, this shortage of skilled staff will accelerate the market penetration rates of POC diagnostic products. Another factor for growth in the point of care market will be driven by elderly patient’s preference for home monitoring and government initiatives aimed at increasing the adoption of point-of-care testing to cut costs.
The global point-of-care testing market is segmented on the basis of product into prescription mode, distribution channel, end user, and geography.
Browse Full Report with Details TOC @ http://databridgemarketresearch.com/reports/point-care-testing-poct-market/
Based on geography, the market is segmented into five geographical regions:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa
The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.
Some major factors driving the market for Point-Of-Care Testing market, such as increasing geriatric population, increase in infectious diseases (hepatitis, HIV infection, influenza, respiratory infections and others), technological advancements, introduction of home-based point of care devices, and rapid economic development in the emerging economies. These factors such as increased awareness among the population, ease of use, rapid test, right dosage to the right place, and enhanced patient compliance are also driving the growth for the point-of-care testing market.
Some of the major players operating in this market are
• Siemens AG
• Abbott Laboratories, Inc.
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• Johnson & Johnson
• Alere Inc.
• Instrumentation Laboratory
• PTS Diagnostics
• Abaxis, Inc.
• Medtronic
• Accriva Diagnostics
• OPTI Medical
• Sienco, Inc.
• Alpha Scientific
• AccuBioTech Co., Ltd.
• ACON Laboratories, Inc.
• Acrongenomics, Inc.
• bioMérieux SA
• Biomerica, Inc
• Atlas Genetics Ltd.
• Alfa Scientific Designs, Inc.
• Bio-Rad Laboratories, Inc.
• Medica Corporation
• Nova Biomedica
Inquiry before Buying @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=point-care-testing-poct-market
Table Of Content:
1. INTRODUCTION
1.1. OVERVIEW OF THE GLOBAL POINT-OF-CARE TESTING MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL POINT-OF-CARE TESTING MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. PRODUCT PIPELINE ANALYSIS
2.2.6. PORTER’S FIVE FORCES MATRIX
2.3. GLOBAL POINT-OF-CARE TESTING MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL POINT-OF-CARE TESTING MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. HIGH PREVALENCE OF INFECTIOUS DISEASES IN DEVELOPING COUNTRIES
4.3.1.2. INCREASING INCIDENCE OF LIFESTYLE DISEASES
4.3.1.3. RISING USAGE OF HOME-BASED POC DEVICES
4.3.1.4. GROWING NUMBER OF REGULATORY APPROVALS FOR NOVEL IMMUNOASSAY TECHNIQUES
4.3.1.5. SHORTAGE OF SKILLED LABORATORY TECHNICIANS INCREASING PREFERENCE OF POC TESTING
4.3.1.6. RISING INCIDENCE OF UNPLANNED PREGANANCIES
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.4. THREATS
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. POINT-OF-CARE TESTING MARKET, BY TYPE
5.1. OVERVIEW
5.2. CARDIOMETABOLIC MONITORING KITS, BY PRODUCT TYPE
5.2.1. CARDIAC MARKERS
5.2.2. BLOOD GAS ELECTROLYTE TESTING KITS
5.2.3. HBA1C TESTING KITS
5.2.4. LIPID TESTING KITS
5.3. INFECTIOUS DISEASE TESTING KITS, BY PRODUCT TYPE
5.3.1. INFLUENZA TESTING KITS
5.3.2. HIV TESTING KITS
5.3.3. HEPATITIS C TESTING KITS
5.3.4. STD TESTING KITS
5.3.5. TROPICAL DISEASE TESTING KITS
5.3.6. HEALTHCARE ASSOCIATED INFECTIONS TESTING KITS
5.3.7. RESPIRATORY INFECTIONS TESTING KITS
5.3.8. OTHERS
5.4. CHOLESTROL TESTING KITS, BY PRODUCT TYPE
5.4.1. PROTHROMBIN TIME TESTING KITS
5.4.2. ACTIVATED CLOTTING TIME TESTING KITS
5.5. BLOOD GLUCOSE TESTING KITS
5.6. PREGNANCY AND FERTILITY TESTING KITS
5.7. TUMOR CANCER MARKERS
5.8. URINALYSIS TESTING KITS
5.9. HEMATOLOGY TESTING KITS
5.10. DRUGS OF ABUSE TESTING KITS
5.11. FECAL OCCULT TESTING KITS
5.12. RAPID COAGULATION TESTING KITS
5.13. OTHERS
6. POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE
6.1. OVERVIEW
6.2. PRESCRIPTION BASED TESTING KITS
6.3. OVER THE COUNTER (OTC) BASED TESTING KITS
7. POINT-OF-CARE TESTING MARKET, BY END-USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. CLINICS
7.4. AMBULATORY CARE
7.5. HOME HEALTHCARE
7.6. RESEARCH LABORATORY
8. POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DIRECT TENDERS
8.3. RETAIL
9. POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE POINT OF CARE TESTING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.1.2. EUROPE
9.1.2.1. GERMANY
9.1.2.2. FRANCE
9.1.2.3. U.K.
9.1.2.4. ITALY
9.1.2.5. SPAIN
9.1.2.6. RUSSIA
9.1.2.7. TURKEY
9.1.2.8. BELGIUM
9.1.2.9. NETHERLANDS
9.1.2.10. SWITZERLAND
9.1.2.11. REST OF EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.3.1. JAPAN
9.1.3.2. CHINA
9.1.3.3. SOUTH KOREA
9.1.3.4. INDIA
9.1.3.5. AUSTRALIA
9.1.3.6. SINGAPORE
9.1.3.7. THAILAND
9.1.3.8. MALAYSIA
9.1.3.9. INDONESIA
9.1.3.10. PHILIPPINES
9.1.3.11. REST OF APAC
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10. POINT-OF-CARE TESTING MARKET: COMPETITIVE LANDSCAPE
10.1. GLOBAL POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.2. U.S. POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.4. APAC POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.5. SOUTH AMERICA POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.6. MEA POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS
10.7. MERGERS & ACQUISITIONS
10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
10.9. EXPANSIONS
10.10. REGULATORY CHANGES
10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11. POINT-OF-CARE TESTING MARKET: COMPANY PROFILES
11.1. ABBOTT LABORATORIES, INC.
11.1.1 COMPANY OVERVIEW
11.1.2 SWOT ANALYSIS
11.1.3 REVENUE ANALYSIS
11.1.4 PRODUCT PORTFOLIO
11.1.5 RECENT DEVELOPEMENTS
11.1.6 DATA BRIDGE ANALYSIS
11.2. ROCHE DIAGNOSTICS LIMITED
11.2.1 COMPANY OVERVIEW
11.2.2 SWOT ANALYSIS
11.2.3 REVENUE ANALYSIS
11.2.4 PRODUCT PORTFOLIO
11.2.5 RECENT DEVELOPEMENTS
11.2.6 DATA BRIDGE ANALYSIS
11.3. SIEMENS AG
11.3.1 COMPANY OVERVIEW
11.3.2 SWOT ANALYSIS
11.3.3 REVENUE ANALYSIS
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPEMENTS
11.3.6 DATA BRIDGE ANALYSIS
11.4. BECKMAN COULTER, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 SWOT ANALYSIS
11.4.3 REVENUE ANALYSIS
11.4.4 PRODUCT PORTFOLIO
11.4.5 RECENT DEVELOPEMENTS
11.4.6 DATA BRIDGE ANALYSIS
11.5. BECTON, DICKINSON AND COMPANY
11.5.1 COMPANY OVERVIEW
11.5.2 SWOT ANALYSIS
11.5.3 REVENUE ANALYSIS
11.5.4 PRODUCT PORTFOLIO
11.5.5 RECENT DEVELOPEMENTS
11.5.6 DATA BRIDGE ANALYSIS
11.6. JOHNSON & JOHNSON
11.6.1 COMPANY OVERVIEW
11.6.2 SWOT ANALYSIS
11.6.3 REVENUE ANALYSIS
11.6.4 PRODUCT PORTFOLIO
11.6.5 RECENT DEVELOPEMENTS
11.6.6 DATA BRIDGE ANALYSIS
11.7. ALERE INC.
11.7.1 COMPANY OVERVIEW
11.7.2 SWOT ANALYSIS
11.7.3 REVENUE ANALYSIS
11.7.4 PRODUCT PORTFOLIO
11.7.5 RECENT DEVELOPEMENTS
11.7.6 DATA BRIDGE ANALYSIS
11.8. INSTRUMENTATION LABORATORY
11.8.1 COMPANY OVERVIEW
11.8.2 SWOT ANALYSIS
11.8.3 REVENUE ANALYSIS
11.8.4 PRODUCT PORTFOLIO
11.8.5 RECENT DEVELOPEMENTS
11.8.6 DATA BRIDGE ANALYSIS
11.9. PTS DIAGNOSTICS
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.6 DATA BRIDGE ANALYSIS
11.10. ABAXIS, INC.
11.10.1 COMPANY OVERVIEW
11.10.2 SWOT ANALYSIS
11.10.3 REVENUE ANALYSIS
11.10.4 PRODUCT PORTFOLIO
11.10.5 RECENT DEVELOPEMENTS
11.10.6 DATA BRIDGE ANALYSIS
11.11. MEDTRONIC
11.11.1 COMPANY OVERVIEW
11.11.2 SWOT ANALYSIS
11.11.3 REVENUE ANALYSIS
11.11.4 PRODUCT PORTFOLIO
11.11.5 RECENT DEVELOPEMENTS
11.11.6 DATA BRIDGE ANALYSIS
11.12. ACCRIVA DIAGNOSTICS
11.12.1 COMPANY OVERVIEW
11.12.2 SWOT ANALYSIS
11.12.3 REVENUE ANALYSIS
11.12.4 PRODUCT PORTFOLIO
11.12.5 RECENT DEVELOPEMENTS
11.12.6 DATA BRIDGE ANALYSIS
11.13. OPTI MEDICAL
11.13.1 COMPANY OVERVIEW
11.13.2 SWOT ANALYSIS
11.13.3 REVENUE ANALYSIS
11.13.4 PRODUCT PORTFOLIO
11.13.5 RECENT DEVELOPEMENTS
11.13.5 DATA BRIDGE ANALYSIS
11.14. SIENCO, INC.
11.14.1 COMPANY OVERVIEW
11.14.2 SWOT ANALYSIS
11.14.3 REVENUE ANALYSIS
11.14.4 PRODUCT PORTFOLIO
11.14.5 RECENT DEVELOPEMENTS
11.14.6 DATA BRIDGE ANALYSIS
11.15. ALPHA SCIENTIFIC
11.15.1 COMPANY OVERVIEW
11.15.2 SWOT ANALYSIS
11.15.3 REVENUE ANALYSIS
11.15.4 PRODUCT PORTFOLIO
11.15.5 RECENT DEVELOPEMENTS
11.15.6 DATA BRIDGE ANALYSIS
11.16. ACCUBIOTECH CO. LTD.
11.16.1 COMPANY OVERVIEW
11.16.2 SWOT ANALYSIS
11.16.3 REVENUE ANALYSIS
11.16.4 PRODUCT PORTFOLIO
11.16.5 RECENT DEVELOPEMENTS
11.16.5 DATA BRIDGE ANALYSIS
11.17. ACON LABORATORIES, INC.
11.17.1 COMPANY OVERVIEW
11.17.2 SWOT ANALYSIS
11.17.3 REVENUE ANALYSIS
11.17.4 PRODUCT PORTFOLIO
11.17.5 RECENT DEVELOPEMENTS
11.17.6 DATA BRIDGE ANALYSIS
11.18. ACRONGENOMICS
11.18.1 COMPANY OVERVIEW
11.18.2 SWOT ANALYSIS
11.18.3 REVENUE ANALYSIS
11.18.4 PRODUCT PORTFOLIO
11.18.5 RECENT DEVELOPEMENTS
11.18.6 DATA BRIDGE ANALYSIS
11.19. BIOMÉRIEUX, BIOMERICA, INC.
11.19.1 COMPANY OVERVIEW
11.19.2 SWOT ANALYSIS
11.19.3 REVENUE ANALYSIS
11.19.4 PRODUCT PORTFOLIO
11.19.5 RECENT DEVELOPEMENTS
11.19.6 DATA BRIDGE ANALYSIS
11.20. ATLAS GENETICS LTD.
11.20.1 COMPANY OVERVIEW
11.20.2 SWOT ANALYSIS
11.20.3 REVENUE ANALYSIS
11.20.4 PRODUCT PORTFOLIO
11.20.5 RECENT DEVELOPEMENTS
11.20.6 DATA BRIDGE ANALYSIS
11.21. ALFA SCIENTIFIC DESIGNS, INC.
11.21.1 COMPANY OVERVIEW
11.21.2 SWOT ANALYSIS
11.21.3 REVENUE ANALYSIS
11.21.4 PRODUCT PORTFOLIO
11.21.5 RECENT DEVELOPEMENTS
11.21.6 DATA BRIDGE ANALYSIS
11.22. BIO-RAD LABORATORIES, INC.
11.22.1 COMPANY OVERVIEW
11.22.2 SWOT ANALYSIS
11.22.3 REVENUE ANALYSIS
11.22.4 PRODUCT PORTFOLIO
11.22.5 RECENT DEVELOPEMENTS
11.22.6 DATA BRIDGE ANALYSIS
11.23. MEDICA CORPORATION
11.23.1 COMPANY OVERVIEW
11.23.2 SWOT ANALYSIS
11.23.3 REVENUE ANALYSIS
11.23.4 PRODUCT PORTFOLIO
11.23.5 RECENT DEVELOPEMENTS
11.23.6 DATA BRIDGE ANALYSIS
11.24. NOVA BIOMEDICAL
11.24.1 COMPANY OVERVIEW
11.24.2 SWOT ANALYSIS
11.24.3 REVENUE ANALYSIS
11.24.4 PRODUCT PORTFOLIO
11.24.5 RECENT DEVELOPEMENTS
11.24.6 DATA BRIDGE ANALYSIS
12. APPENDIX
12.1. SOURCES AND BIBLIOGRAPHY
12.2. RELATED REPORTS
12.3. A GLIMSE OF DATA BRIDGE MARKET RESEARCH FACTBOOK
13. ABOUT DATA BRIDGE MARKET RESEARCH
Related Report
Global Hemostats Market- Trends and Forecast to 2024
Global Hemostats Market, By Product Type (Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based Hemostat), By Indication (Wound Closure, Surgery), By End-User (Hospitals, Clinics, Ambulatory Centers, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Trends and Forecast to 2024
http://databridgemarketresearch.com/reports/medical-devices/general-surgery-medical-devices/global-hemostats-market-trends-forecast-2024/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Ankit Singh
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog http://databridgemarketresearch.com/blog/